What is Jinarc 45 mg + 15 mg, tablets used for?

( ARTG ) JINARC is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see PHARMACOLOGY).

What are the side effects of Jinarc 45 mg + 15 mg, tablets?

You can help ensure medicines are safe by reporting the side effects you experience. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Can Jinarc 45 mg + 15 mg, tablets be used during pregnancy?

( AHT ) For the active ingredient tolvaptan You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Who manufactures Jinarc 45 mg + 15 mg, tablets?

Otsuka Pharmaceutical (Switzerland) GmbH (CH)

What ATC class does Jinarc 45 mg + 15 mg, tablets belong to?

Jinarc 45 mg + 15 mg, tablets: ATC C03XA01. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

OTC

Jinarc 45 mg + 15 mg, tablets

Data updated: 2026-04-11

Available in:

🇨🇿🇩🇪🇬🇧🇸🇰

Form

—

Dosage

—

Route

—

Storage

—

About This Product

Manufacturer

Otsuka Pharmaceutical (Switzerland) GmbH

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.